Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report released on Tuesday, Benzinga reports. They currently have a $46.00 price objective on the stock. BTIG Research’s price target points to a potential upside of 69.53% from the company’s current price.

A number of other analysts also recently commented on MAZE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Trading Up 21.2%

Shares of MAZE stock traded up $4.74 on Tuesday, reaching $27.13. 1,912,152 shares of the stock were exchanged, compared to its average volume of 646,265. The stock has a market cap of $1.51 billion, a PE ratio of -10.76 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The stock has a 50 day moving average price of $27.24 and a 200 day moving average price of $29.42. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). Equities research analysts forecast that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jason V. Coloma sold 11,411 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the completion of the transaction, the chief executive officer directly owned 27,362 shares in the company, valued at approximately $711,685.62. The trade was a 29.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the transaction, the insider owned 32,316 shares in the company, valued at $840,539.16. The trade was a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 191,459 shares of company stock worth $5,263,539 in the last ninety days. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $48,000. Royal Bank of Canada raised its holdings in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after acquiring an additional 1,383 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Maze Therapeutics in the second quarter worth about $80,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the fourth quarter valued at about $145,000. Finally, IFP Advisors Inc bought a new stake in shares of Maze Therapeutics in the fourth quarter worth $146,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.